BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

BMC CANCER is a prestigious, peer-reviewed journal dedicated to advancing the field of cancer research and oncology since its inception in 2001. Published by BMC, a leading name in open-access publishing, this journal plays a crucial role in providing researchers, professionals, and students with a platform for high-quality scientific discourse. With an impressive impact factor, BMC CANCER is ranked in the Q2 quartile across multiple categories, including Cancer Research, Genetics, and Oncology, reflecting its commitment to impactful research and rigorous peer-review standards. The journal ensures broad accessibility to its content through its Open Access model, allowing findings to reach a global audience without financial barriers. The editorial board consists of recognized experts committed to fostering innovation and collaboration within the cancer research community. Researchers working at the intersection of cancer biology, treatment options, and genetic influences will find BMC CANCER an invaluable resource for sharing their findings and engaging with the latest developments in the field.

The Breast Journal, published by Wiley-Hindawi, is a distinguished Open Access journal dedicated to the fields of internal medicine, oncology, and surgery with a particular focus on breast health and disease. Since its inception in 1995, the journal has become an essential resource for researchers and clinicians, facilitating the dissemination of high-quality research and innovative clinical practices. With an impact factor reflecting robust scholarly influence and a ranking in the Q3 quartile for both internal medicine and oncology, as well as Q2 in surgery, it showcases significant contributions that advance knowledge and improve patient outcomes. Offering unparalleled access to its articles, The Breast Journal aims to support a global audience in exploring the multifaceted challenges and breakthroughs in breast-related health, making it a vital platform for shared learning and scientific discourse.

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

The World Journal of Oncology, published by ELMER PRESS INC, is a vibrant platform for disseminating groundbreaking research and advancements in the field of oncology. With its ISSN 1920-4531 and E-ISSN 1920-454X, this journal is dedicated to publishing high-quality studies that enhance our understanding of cancer and its treatment. The journal is recognized for its significant contributions, evidenced by its Q2 classification in both Cancer Research and Oncology categories in 2023, and accolades such as a Scopus rank of #126/404 in Medicine _ Oncology. Catering to the needs of researchers, professionals, and students, the World Journal of Oncology offers an essential resource for the latest scientific insights and clinical practices, ensuring the global oncology community remains informed and engaged. The journal operates under a selective publication model, maintaining rigor in peer review while facilitating knowledge sharing across converged years from 2014 to 2016 and 2020 to 2024, further establishing its importance in the ongoing fight against cancer.

PROSTATE is a premier, peer-reviewed journal published by Wiley, focusing on the critical fields of urology and oncology. With an established history since 1980 and a projected convergence through 2024, this influential journal serves as a vital resource for researchers, clinicians, and students alike. It holds a prestigious position in the academic landscape, classified in the Q1 category for Urology and Q2 in Oncology as of 2023, demonstrating its significant contribution to these disciplines. With a Scopus rank of #23 in Urology and #169 in Oncology, PROSTATE is pivotal for advancing knowledge and fostering innovation in prostate research, treatment, and overall male health. The journal aims to publish high-quality original articles, reviews, and clinical studies that address the complexities of prostate-related conditions, ultimately seeking to improve patient outcomes and propagate best practices in the medical community.

Indian Journal of Gynecologic Oncology, published by SPRINGER INDIA, is a distinguished platform dedicated to the rigorous dissemination of research and advancements in the fields of gynecologic oncology. With an ISSN of 2363-8397 and E-ISSN of 2363-8400, the journal aims to bridge the gap between clinical practice and research in obstetrics and gynecology, while also addressing pivotal issues in oncology. Operating from its headquarters in New Delhi, India, the journal has been active since 2016 and is recognized within the academic community, achieving a Category Quartile of Q3 in Obstetrics and Gynecology and Q4 in Oncology as of 2023. Although currently not an open-access journal, it offers extensive access options for subscribing institutions and professionals. With its commitment to high-quality peer-reviewed content, the journal serves as a vital resource for researchers, clinicians, and students dedicated to advancing knowledge and improving patient outcomes in gynecologic cancers.